Utilization and Duration of Systemic Corticosteroid Exposure in Atopic Dermatitis Patients After the Introduction of Advanced Therapies: A Population-Based Study From the United States
Bunick C, Vleugels R, Lebwohl M, Grada A, Yue E, Wegrzyn L, D'Andrea E. Utilization and Duration of Systemic Corticosteroid Exposure in Atopic Dermatitis Patients After the Introduction of Advanced Therapies: A Population-Based Study From the United States. SKIN The Journal Of Cutaneous Medicine 2024, 8: s448. DOI: 10.25251/skin.8.supp.448.Peer-Reviewed Original ResearchSystemic corticosteroid treatmentSystemic corticosteroidsAtopic dermatitisLong-term usersAdvanced therapiesContinuous health insurance enrollmentUsage of non-steroidal anti-inflammatory drugsRelevant proportion of patientsManagement of atopic dermatitisOral systemic corticosteroidsSystemic corticosteroid exposureClinical guidelinesHistory of malignancyProportion of patientsImmuno-mediated diseasesNon-steroidal anti-inflammatory drugsPercentage of patientsAtopic dermatitis patientsIntroduction of advanced therapiesAdvanced systemic treatmentsPopulation-based studyAnti-inflammatory drugsShort-term usersPrescription of biologicsCorticosteroid exposure681 - Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data
Vleugels R, Grada A, Yue E, Bunick C, Galimberti F, Krueger W. 681 - Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data. British Journal Of Dermatology 2024, 191: ljae266.055. DOI: 10.1093/bjd/ljae266.055.Peer-Reviewed Original ResearchNon-melanoma skin cancerRisk of malignancyModerate-to-severe diseaseCohort entry dateAtopic dermatitisRheumatoid arthritisFollow-upModerate-to-severe atopic dermatitisSkin cancerNon-AD cohortIncidence of malignancyNonmelanoma skin cancerSubgroup of patientsNon-AD controlsFollow-up periodCox proportional hazards modelsChronic liver diseaseEffect of disease activityInternational Classification of Diseases (ICD)-9Population-based studyProportional hazards modelClinformatics Data MartSystemic therapyClaims-based studyOptum Clinformatics Data Mart697 - Risk of non-melanoma skin cancer in patients with moderate-to-severe atopic dermatitis: a United States population-based study using claims data
Lebwohl M, Yue E, Krueger W, Berman B, Bunick C, Schlesinger T, Grada A. 697 - Risk of non-melanoma skin cancer in patients with moderate-to-severe atopic dermatitis: a United States population-based study using claims data. British Journal Of Dermatology 2024, 191: ljae266.071. DOI: 10.1093/bjd/ljae266.071.Peer-Reviewed Original ResearchNon-melanoma skin cancerRisk of non-melanoma skin cancerModerate-to-severe diseaseAtopic dermatitisNon-AD cohortRheumatoid arthritisControl cohortNon-melanoma skin cancer riskModerate-to-severe atopic dermatitisNon-melanoma skin cancer incidenceMultivariate Cox proportional hazards modelSkin cancerModerate-to-severe ADCohort entry dateSquamous cell carcinomaMatched control cohortIntermittent sun exposureFollow-up timeNon-AD controlsRetrospective observational studyCox proportional hazards modelsEffect of disease activityPopulation-based studyProportional hazards modelClinformatics Data Mart